

H1N1 INFLUENZA 2009–10 VACCINE VAC-FACT

Rev Dec 4 2009



Did You Know – With 2 types of influenza vaccine, seasonal & H1N1, and as many as 14 different product presentations from 5 different manufacturers, there is great potential for administration errors.

To minimize this potential see the back of this VAC-FACT for a table describing approved uses of all state-supplied seasonal & H1N1 influenza vaccines.
SUGGESTION: Be sure to **CHECK YOUR VIALS** 3 times before administration to make sure of the product and dosage that you are using.

CROSS PROTECTION	H1N1 influenza vaccine (monovalent) will NOT provide protection against seasonal influenza Seasonal influenza vaccine (trivalent) will NOT provide protection against H1N1 influenza			
SAFETY	H1N1 vaccine is produced exactly the same way as seasonal flu vaccine. It is simply a new virus strain. Seasonal flu vaccine strains may change every year. Immunogenicity and safety study results are similar to those observed for seasonal influenza vaccines. For more information go to http://www.cdc.gov/h1n1flu/vaccination/			
MONITORING	FDA and CDC are closely monitoring the 2009 H1N1 influenza vaccines as well as all other vaccines. To report any suspected adverse reaction go to the Vaccine Adverse Event Report System (VAERS) website http://vaers.hhs.gov/ Anyone can file a VAERS report.			
SUPPLY *	Vaccine supply will increase weekly through the fall & winter. Once supply has satisfied demand among target groups (see back of this VAC-FACT), vaccination should be expanded to all persons including those aged ≥65 years. VFC screening NOT required			
H1N1 VACCINE DATA ENTRY CODES	Product administered	VAC TRAK	CVX	RPMS
	MedImmune – 0.2mL intranasal sprayer	Novel H1N1, Nasal	125	H1N1-NASAL
	Sanofi Pasteur – Pre-filled 0.25mL syringe	Novel H1N1, Presv free, 6-35 Mos	126	H1N1-PFREE
	Sanofi Pasteur – Pre-filled 0.5mL syringe OR Single dose 0.5mL vial	Novel H1N1, Presv Free, 36+ Mos	126	H1N1-PFREE
	CSL Biotherapies – Pre-filled 0.5mL syringe	Novel H1N1, Presv Free, 36+ Mos	126	H1N1-PFREE
	Novartis – Pre-filled 0.5mL syringe	Novel H1N1, Presv Free, 48+ Mos	126	H1N1-PFREE
	Sanofi Pasteur – Multi-dose (10+ doses) 5mL vial (0.25mL for 6-35mos OR 0.5mL for 36+mos)	Novel H1N1, Injectable, 36+ Mos (use also for doses given to 6-35mos)	127	H1N1
	CSL – Multi-dose (10+ doses) 5mL vial (0.25mL for 6-35mos OR 0.5mL for 36+mos)	Novel H1N1, Injectable, 36+Mos (use also for doses given to 6-35mos)	127	H1N1
	Novartis – Multi-dose (10 @ 0.5mL) 5mL vial	Novel H1N1, Injectable, 48+ Mos	127	H1N1
	GlaxoSmithKline - Multi-dose (10 @ 0.5mL) 5mL vial	Novel H1N1, Injectable, 18+ Yrs	127	H1N1

For general information SEE PACKAGE INSERT(S). All FDA licensed vaccine package inserts are online: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833

- * For Alaska-specific information go to the Alaska VacTrAK homepage www.vactrak.alaska.gov or
- Alaska H1N1 Epidemiology Bulletin Oct. 14, 2009: http://www.epi.alaska.gov/bulletins/docs/b2009_27.pdf or
 - Call the Alaska Immunization Program Helpline at 888-430-4321 or 269-8088 in Anchorage or
 - Call the VacTrak Support line at 866-702-8725 or 269-0312 in Anchorage or go to www.vactrak.alaska.gov
 - This and other VAC-FACTS are online at www.vaccinate.alaska.gov Click on VAC-FACT sheets.

Vaccinate Alaska Coalition (VAC) seeks to protect the health of all Alaskans by decreasing vaccine-preventable disease through positive immunization promotion campaigns, support of local immunization coalitions, and increased private and public provider participation in immunization activities. www.vaccinate.alaska.gov

2009-10 APPROVED USE OF ALASKA STATE-SUPPLIED SEASONAL AND H1N1 INFLUENZA VACCINES

	SEASONAL INFLUENZA VACCINE (Trivalent)	H1N1 VACCINE (Monovalent)
TARGET GROUPS RECOMMENDED TO RECEIVE VACCINE	<ul style="list-style-type: none"> Children 6 months-18 years Adults 50 years and older Pregnant women Persons with chronic medical conditions* or immunodeficiency Healthcare workers Household contacts of children <5 years and adults ≥50 years 	<ul style="list-style-type: none"> Pregnant women Household contacts/caregivers of infants <6 months Healthcare workers and emergency medical personnel Persons 6 months-24 years Persons 25 years–64 years with chronic medical conditions* When adequate supply – anyone who wants to be vaccinated
INJECTABLE INTRAMUSCULAR INACTIVATED INFLUENZA VACCINE		
INJECTABLE VACCINE Indication & dosage by product	<p>All Providers</p> <ul style="list-style-type: none"> 6-35 months - dosage 0.25 mL route intramuscular (IM) <ul style="list-style-type: none"> Fluzone® Sanofi - single-dose pre-filled syringe preservative-free Fluzone® Sanofi – 0.25 mL drawn from multi-dose 5 mL vial[^] <p>Private Providers</p> <ul style="list-style-type: none"> 36 months–18 years – dosage 0.5 mL route IM <ul style="list-style-type: none"> Fluzone® Sanofi – 0.5 mL drawn from multi-dose 5 mL vial[^] <p>Public Health & Alaska Native Health Corp Providers</p> <ul style="list-style-type: none"> 36 months & older – dosage 0.5 mL route IM <ul style="list-style-type: none"> Fluzone® Sanofi – 0.5 mL drawn from multi-dose 5 mL vial[^] 48 months (4 years) & older – dosage 0.5 mL route IM <ul style="list-style-type: none"> Fluvirin® Novartis – 0.5 mL drawn from multi-dose 5 mL vial[^] 	<p>All Providers</p> <ul style="list-style-type: none"> 6-35 months – dosage 0.25 mL route intramuscular (IM) <ul style="list-style-type: none"> Sanofi – single-dose syringe preservative free (pink plunger rod) Sanofi – 0.25 mL drawn from multi-dose 5 mL vial[^] CSL Biotherapies – 0.25 mL drawn from multi-dose 5 mL vial[^] 36 months (3 years) & older – dosage 0.5 mL route IM <ul style="list-style-type: none"> Sanofi - 0.5 mL drawn from multi-dose 5 mL vial[^] Sanofi - 0.5 mL single-dose syringe preservative-free Sanofi - 0.5 mL single-dose vial preservative-free CSL Biotherapies – 0.5mL single-dose syringe preservative-free CSL Biotherapies – 0.5 mL drawn from multi-dose 5 mL vial[^] 48 months (4 years) & older - dosage 0.5 mL route IM <ul style="list-style-type: none"> Novartis - 0.5 mL drawn from multi-dose 5 mL vial[^] Novartis - 0.5 mL single-dose syringe preservative free[#] 18 years & older – dosage 0.5 mL route IM <ul style="list-style-type: none"> GlaxoSmithKline (GSK) - 0.5mL drawn from multi-dose 5 mL vial[^]
NASAL SPRAY LIVE ATTENUATED INFLUENZA VACCINE (LAIV)		
NASAL SPRAY (LAIV) VACCINE Indication & dosage	<ul style="list-style-type: none"> 2 years-18 years - 0.2 mL sprayer – all providers. FluMist® MedImmune - Administer 0.1 mL in each nostril 	<ul style="list-style-type: none"> 2 years-49 years – 0.2 mL sprayer – all providers MedImmune - Administer 0.1 mL in each nostril
CONTRAINDICATIONS for nasal spray LAIV vaccines May be candidate for injectable	<ul style="list-style-type: none"> Do not administer if <2 years or >49 years Do not administer if pregnant Do not administer if chronic medical conditions* Do not administer if child <5 years with history of wheezing in past 12 months, or in older child with asthma Do not administer to close contact of patient with severe immunosuppression requiring protective isolation Do not administer to anyone who received LAIV - seasonal or H1N1 - at any time within the preceding 4 weeks 	
SPECIAL NOTE nasal spray LAIV	<p>DO NOT administer seasonal LAIV (FluMist® nasal spray) and H1N1 LAIV (nasal spray) vaccine at the same time. Separate doses by 28 days. Seasonal or H1N1 vaccines may be administered simultaneously with all other (including live virus) vaccines EXCEPT as stated above. If not administered simultaneously live virus vaccines require a minimum interval of 28 days between doses.</p>	
CONTRAINDICATIONS for all influenza vaccines	<ul style="list-style-type: none"> Do not administer if anaphylaxis or life-threatening reaction to a previous influenza vaccination Do not administer if allergy to eggs or any vaccine component – see package insert. All product inserts are online at: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833 	
PRECAUTIONS for all influenza vaccines	<ul style="list-style-type: none"> Moderate or severe illness. A person with a mild cold or other mild illness, with or w/out fever, may be vaccinated. Guillain Barré syndrome within 6 weeks of a previous influenza vaccination. 	
NEED 2 DOSES THIS SEASON? Do not reserve vaccine for 2 nd dose	<p>SEASONAL INFLUENZA VACCINE – If 8 or younger – 2 doses administered 4 weeks apart if receiving first ever flu dose or if only 1 dose received last season. Use of same vaccine is preferred however seasonal influenza vaccines may be considered interchangeable.</p>	<p>H1N1 VACCINE – If 9 or younger - 2 doses administered 4 weeks apart (valid dose if ≥21 days apart). Use of same vaccine is preferred however H1N1 vaccines may be considered interchangeable.</p>

* chronic pulmonary (including asthma), cardiovascular (excluding hypertension), renal, hepatic, cognitive, neurologic/neuromuscular (e.g. cerebral palsy), hematologic, or metabolic disorders (e.g. diabetes); immunosuppression including that caused by medications or HIV; children through age 18 on long-term aspirin therapy

[^] preservative is thimerosal 25 mcg per 0.5 mL dose

[#] may contain trace (<1 mcg) amount of thimerosal

This and other VAC-FACTs are online at www.vaccinate.alaska.gov Click on VAC-FACT sheets

Rev Dec 4 2009